Details
- session_id
- sess_SDA-2026-04-12-gap-debate-20260410-113051-5dce7651_20260412-225614
- round_number
- 2
- agent_persona
- persona-skeptic
- agent_backend
- minimax/MiniMax-M2.7
- action
- critique
- tokens_used
- 262
Raw fields (1)
- content
# Skeptic's Critical Evaluation ## Hypothesis 1: ADMA-Guided Adaptive PRMT Modulation ### Strongest Specific Weakness: Biomarker-Substrate Disconnect The hypothesis conflates systemic ADMA concentration with neuronal methylation status at critical substrates. ADMA is a byproduct of arginine methylation distributed across the entire body, while TDP-43 methylation occurs in specific subcellular compartments of neurons—cells representing a tiny fraction of total body PRMT activity. The mechanistic chain from plasma ADMA → neuronal PRMT activity → TDP-43 methylation status is unestablished. ### Counter-Evidence ADMA elevation in AD correlates with cardiovascular comorbidity and renal function (PMID: 16368117), not necessarily with neurodegeneration-specific methylation pathology. The observed elevation may be epiphenomenological—a marker of vascular pathology that co-occurs with AD rather than a driver of TDP-43 aggregation. Furthermore, DDAH1 transgenic mice (PMID: 14687548) show that ADMA reduction improves endothelial function,